Society President Dr Lynette Nieman explains why the organization is supporting the upcoming March for Science.

Patient resistance is a well-known barrier to the use of insulin, but what about clinician resistance?

Drs Shubrook and Bertheau discuss alternatives to branded basal insulins and how to make the switch.

What are the pros and cons of using premixed insulin, both human and analog, in patients with type 2 diabetes?

If Dr Walton-Shirley were designing the next trial on PCSK9 inhibitors, she'd include a Mediterranean diet and exercise arm. She and Dr Mandrola ponder alternative uses of our healthcare dollars.

Drs Harrington and Yancy review the efficacy and cognitive safety data for the PCSK9 inhibitor evolocumab, presented at the American College of Cardiology sessions.

Dr John Buse highlights some of the new drugs and devices being developed for type 2 and type 1 diabetes.

Dr Szczech provides a sobering view on what extreme actions uninsured immigrants are taking to push their symptom boundaries to near death every week in order to get emergent hemodialysis.

We know that insulin can help patients with diabetes, but can it also place them in harm's way?

How can we address patients' fears about insulin? Dr Shubrook speaks with Dr Jim LaSalle about the benefits of earlier use of insulin in patients with type 2 diabetes.